HOUSTON, Nov. 3, 2025 /PRNewswire/ -- AAVivo, Inc., a pioneering biotechnology company developing novel, precision targeted biotherapeutics to enable in vivo generation of CAR-T cells, today announced a presentation at the Society for Immunotherapy of Cancer 2025, which is being held November 5-9, in National Harbor, MD.
AAVivo will present a poster titled, "In Vivo Generation of CD19-Specific CAR-T Cells Using a Novel AAV Gene Therapy Platform to Treat B Cell Malignancies". The poster describes the Company's lead candidate, AVO-100, a gene therapy that is designed using adeno-associated viruses (AAV) with capsids containing T cell-targeting (TCeT) moieties to produce CD19-specific CAR-T cells in patients. Preclinical data to date suggest that AVO-100 can be used to generate CD19-specific T cells from non-activated T cells in human PBMCs both in vitro and in vivo and the CAR-T cells can control the growth of Raji lymphoma in vitro and in NSG mice.
"We are pleased that a poster highlighting the potential of our iAAV platform to rapidly enable in vivo generation of CAR-T cells was accepted for presentation at SITC 2025," said Haifeng Chen, Ph.D. Chief Technology Officer & Founder of AAVivo. "Having this research accepted for presentation at SITC, one of the preeminent oncology conferences, showcases the breadth of AAVivo's patented technologies and the potential of AVO-100, our lead program targeting B-cell malignancies."
Details of the poster being presented at SITC 2025 are as follows:
Abstract Number: 1001
Abstract Title: In Vivo Generation of CD19-Specific CAR-T Cells Using a Novel AAV Gene Therapy Platform to Treat B Cell Malignancies
Presenting Author: Haifeng Chen, Ph.D. Chief Technology Officer & Founder, AAVivo, Inc.
Session Date: Friday, Nov. 7
About AAVivo, Inc.
AAVivo, Inc. is a biotechnology innovator advancing precision-targeted biotherapeutics through its proprietary iAAV-based platform. By harnessing a suite of patented technologies, AAVivo enables the in vivo generation of CAR-T cells, offering a transformative alternative to traditional CAR-T therapies. The company's cutting-edge platform includes:
Together, these innovations provide higher yields, enhanced potency without the need for lymphodepletion, and superior scalability, unlocking the potential of AAV vectors across diverse indications. AAVivo's development pipeline, which includes AVO-100, the company's lead product for B cell malignancies, as well as AVO-200 and AVO-300 for solid tumors, positions the company as a leader in the rapidly growing gene therapy market, offering investors a unique opportunity to support a scalable, high-impact biotech platform. AAVivo is headquartered in Houston, Texas. For more information, visit https://aavivo.com/.
Contact
Tiberend Strategic Advisors, Inc.
Investor Relations
Jon Nugent
205-566-3026
jnugent@tiberend.com
Media Relations
Casey McDonald
646-577-8520
cmcdonald@tiberend.com
SOURCE AAVivo, Inc.